The leading conference for innovation in cancer care delivery is now available on-demand! Participation in the enduring activities of the ACCC 37th [Virtual] National Oncology Conference will be available for 12 months and will award continuing education hours for physicians, nurses, pharmacists, and administrators as appropriate.

With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.

In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.